Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | Phase 1 | terminated | Oct 26, 2021 | Medical College of Wisconsin | Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All… | Other (stated, no rule matched) |
| NCT04996745 | Taking POSNA's OrthoKids to the People | N/A | withdrawn | Aug 9, 2021 | Louisiana State University Health Sciences Center in New Orleans | Submitted in error | Other (stated, no rule matched) |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With… | Phase 1 / Phase 2 | terminated | Nov 16, 2018 | Celgene | Absence of significant therapeutic benefit over existing therapies | Other (stated, no rule matched) |
| NCT04554459 | Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult…(Pona-CELL) | Phase 2 | terminated | Sep 18, 2020 | Institute of Hematology and Blood Transfusion, Czech Republic | slower recruitment rate; | Enrollment / accrual |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic… | — | terminated | Apr 21, 2021 | University of Washington | The study ended earlier than anticipated due to slow accrual. | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell… | — | terminated | Dec 9, 2022 | Mustang Bio | Business Reasons | Sponsor / business decision |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With… | Phase 1 | terminated | Sep 14, 2018 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | Phase 1 / Phase 2 | terminated | Mar 9, 2022 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | Phase 1 / Phase 2 | withdrawn | Jul 7, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual, no participants enrolled | Enrollment / accrual |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic… | Phase 2 | terminated | Apr 18, 2016 | TG Therapeutics, Inc. | (Strategic/Business Decision) | Sponsor / business decision |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed…(HEM-iSMART A) | Phase 1 / Phase 2 | withdrawn | Feb 23, 2023 | Princess Maxima Center for Pediatric Oncology | Company stopped development and production of one of the IMP's. | Sponsor / business decision |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and… | Phase 1 | terminated | Jun 30, 2006 | Kyowa Kirin, Inc. | Terminated due to suboptimal dosing schedule | Other (stated, no rule matched) |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute… | Phase 2 | withdrawn | Jan 18, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT05410574 | Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic Leukemia | N/A | terminated | Jun 8, 2022 | Washington University School of Medicine | Insufficient staff | Other (stated, no rule matched) |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and…(ULTRA-V) | Phase 2 / Phase 3 | terminated | Jan 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT05465876 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL(PACE-CLL) | Phase 2 | withdrawn | Jul 20, 2022 | Sunnybrook Health Sciences Centre | Funding pulled | Funding |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell… | Phase 1 / Phase 2 | withdrawn | Mar 31, 2017 | Zhujiang Hospital | The company did not offer the appropriate CART services. | Sponsor / business decision |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | Phase 1 / Phase 2 | withdrawn | Nov 14, 2022 | Zhujiang Hospital | The company failed to provide corresponding CART services. | Sponsor / business decision |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived… | Phase 1 | terminated | May 12, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Safety endpointreached | Safety / toxicity |
| NCT03982992 | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab(DLI-TARGET) | Phase 2 | withdrawn | Jun 12, 2019 | Ludwig-Maximilians - University of Munich | Lack of potential study subjects due to a change of standard of care treatment outside of clinical… | Other (stated, no rule matched) |
| NCT04968860 | Oral Health Condition and Quality of Life in Children With Leukemia | — | terminated | Jul 20, 2021 | Paulo Sergio da Silva Santos | Low casuistry that did not allow the study to continue | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06247540 | Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's… | Phase 2 | withdrawn | Feb 8, 2024 | Northwestern University | Funding | Funding |
| NCT04845035 | Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia… | Phase 2 | withdrawn | Apr 14, 2021 | University of Michigan Rogel Cancer Center | The PI plans to revise the study design in a new protocol | Other (stated, no rule matched) |
| NCT01186328 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute… | Phase 1 | terminated | Aug 23, 2010 | Therapeutic Advances in Childhood Leukemia Consortium | Enzon Pharmaceuticals decided to end its development of EZN-3042. | Other (stated, no rule matched) |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | Phase 2 | terminated | Mar 8, 2021 | Prof. Christina Peters | Terminated by Amgen Limited | Other (stated, no rule matched) |
| NCT02580981 | Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses | N/A | terminated | Oct 20, 2015 | New Mexico Cancer Research Alliance | Staffing | Other (stated, no rule matched) |
| NCT04803123 | Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r… | Early Phase 1 | terminated | Mar 17, 2021 | Dorothy Sipkins, MD, PhD | Sponsor halted clinical development of study drug | Other (stated, no rule matched) |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI)… | Phase 1 / Phase 2 | withdrawn | Jan 21, 2022 | Naoyuki G. Saito, M.D., Ph.D. | insufficient staff and updates in standard practice have made it difficult to recruit participants | Enrollment / accrual |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Jul 27, 2021 | Vincerx Pharma, Inc. | Slow enrollment | Enrollment / accrual |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously… | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | Sumitomo Pharma America, Inc. | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to… | Other (stated, no rule matched) |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/… | Phase 2 | terminated | May 5, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Phase 1 | terminated | Jan 29, 2020 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic…(REVEAL) | — | suspended | Sep 6, 2018 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05961696 | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic… | Phase 1 | withdrawn | Jul 27, 2023 | M.D. Anderson Cancer Center | 0 accrual | Enrollment / accrual |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | Phase 1 / Phase 2 | terminated | Feb 19, 2014 | Bellicum Pharmaceuticals | Sponsor decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 19, 2024source: clinicaltrials